Aequus Pharmaceuticals (CVE:AQS) Hits New 12-Month Low – Should You Sell?

Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 3000 shares trading hands. The stock had previously closed at C$0.01.

Aequus Pharmaceuticals Stock Performance

The firm’s 50 day simple moving average is C$0.01 and its 200 day simple moving average is C$0.02. The firm has a market cap of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88.

About Aequus Pharmaceuticals

(Get Free Report)

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.

See Also

• Five stocks we like better than Aequus Pharmaceuticals
• Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
• Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
• Stock Sentiment Analysis: How it Works
• Netflix Is On Track To Hit $1,000 By Christmas
• The Most Important Warren Buffett Stock for Investors: His Own
• UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype